Topic: vaccine manufacturing
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.
Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.
Merck is increasing its HPV vaccine production capacity, but it still won't be enough to meet the full demand in China, a company spokesperson said.
Ex-Roche scientists were charged with stealing trade secrets; Astellas invested in gene and cell therapy; Takeda touted growth in key focus areas.
If the German contract manufacturer delivers all projects over the 10-year course, it could receive up to $80 million.
A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.
No production or safety problems were found at the other 45 vaccine manufacturers in China, the country's drug regulator says.
Here is some other vaccine news of note for the week.
A blockchain-based drug and vaccine traceability system, which the developer says records all data in the vaccine supply chain, will debut in Shanghai.
Changchun Changsheng “systematically fabricated production and testing records,” a Chinese central government investigation team reported.